101. Optimal sequence of antisense DNA to silence YB-1 in lung cancer by use of a novel polysaccharide drug delivery system
- Author
-
Shinichi Mochizuki, Kazuo Sakurai, Shohei Nagao, Nobuaki Fujiwara, Hiroto Izumi, and Yasuo Morimoto
- Subjects
0301 basic medicine ,Cancer Research ,Lung Neoplasms ,Cell Survival ,Sizofiran ,Cell ,Biology ,medicine.disease_cause ,DNA, Antisense ,Cell Line ,03 medical and health sciences ,chemistry.chemical_compound ,Drug Delivery Systems ,0302 clinical medicine ,medicine ,Humans ,Lectins, C-Type ,Gene Silencing ,Viability assay ,Base Sequence ,Oncogene ,Cancer ,Cell cycle ,medicine.disease ,Molecular biology ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Y-Box-Binding Protein 1 ,Carcinogenesis ,DNA - Abstract
Silencing Y-box binding protein 1 (YB-1) can be an excellent target for cancer therapy and many lung cancer cells express the polysaccharide-recognition receptor Dectin-1. We designed a Dectin-1 targeting vehicle delivering YB-1-antisense DNA. First, we selected five optimal antisense DNA sequences to silence YB-1 from among 153 candidates. We chose the sequence closest to the start codon (AS014), and attached dA40 to the 3' end; dA40 promotes complex formation with a β-(1➝3)-d-glucan called schizophyllan (SPG). The resultant complexes were applied to 12 human-oriented lung cancer cell lines, and cell viability was examined. The cell lines exhibited decreased viability and showed strong affinity to bind SPG, suggesting the AS014/SPG complex entered the cells via the Dectin-1 mediated pathway.
- Published
- 2016
- Full Text
- View/download PDF